艾滋病治疗用药多替阿巴拉米片效果如何？

(Suimeikai) is suitable for the treatment of adults and adolescents over 12 years old (weight at least 40kg) infected with human immunodeficiency virus (HIV). On January 22, 2018, GlaxoSmithKline (GSK) announced that Triumeq (Dolutegravir), a single-tablet compound preparation for the treatment of HIV, was officially launched in mainland China. The drug is the only three-in-one compound drug containing dolutegravir. It takes one tablet once a day and has the characteristics of high efficacy, good tolerance, high resistance barrier and few drug interactions.

Specifications of Dolutegravir Tablets (Simeike): Each tablet contains 50 mg of dolutegravir (DTG), 600 mg of abacavir (ABC) and 300 mg of lamivudine (3TC). Dolutegra Abalamid Tablets (Suimeike) should be taken orally under the guidance of a physician with experience in treating HIV infection. This product is not affected by food. Dosage: One tablet, once daily. It is not recommended for those whose creatinine clearance is less than 50ml/min.

Trimax is a drug containing three active ingredients. Existing research shows that one year (48 weeks) after treatment with Trimax, 93% of HIV-infected patients became negative in viral load.

(Suimeikan) cannot be used for individuals who carry the HLA-B*5701 gene. Patients carrying this gene will have a high risk of severe hypersensitivity reactions (type I allergic reactions) when using Suimeikan. Therefore, before taking Suimeikai, you need to complete the test to determine whether you carry the special type of "HLA-B*5701" gene.

Recommended related hot articles: /newsDetail/82196.html